Table 2 Frequencies of visceral leishmaniasis relapse and death according to general variables and drug therapy
Variables | Total (n = 169) | Follow-up adverse outcomes | ||||||
|---|---|---|---|---|---|---|---|---|
VL relapse (n = 70, 41.4%) | P | Death (n = 19, 11.2%) | P | |||||
Yes | No | Yes | No | |||||
n | (%) | (%) | (%) | (%) | (%) | |||
Sex | .461 | 1.000 | ||||||
Male | 151 | (89.3) | (42.4) | (57.6) | (11.3) | (88.7) | ||
Female | 18 | (10.7) | (33.3) | (66.7) | (11.1) | (88.9) | ||
Age group | .120 | .973 | ||||||
19 to 29 years | 40 | (23.7) | (30.0) | (70.0) | (10.0) | (90.0) | ||
30 to 39 years | 68 | (40.2) | (42.7) | (57.3) | (11.8) | (88.2) | ||
40 to 49 years | 47 | (27.8) | (53.2) | (46.8) | (10.6) | (89.4) | ||
50 years or more | 14 | (8.3) | (28.6) | (71.4) | (14.3) | (85.7) | ||
VL drug therapy | .156 | .585 | ||||||
Liposomal amphotericin B | 123 | (72.8) | (46.3) | (53.7) | (13.0) | (87.0) | ||
Amphotericin B deoxycholate | 27 | (16.0) | (33.3) | (66.7) | (3.7) | (96.3) | ||
Meglumine antimoniate | 10 | (5.9) | (20.0) | (80.0) | (10.0) | (90.0) | ||
More than one drug | 9 | (5.3) | (22.2) | (77.8) | (11.1) | (88.9) | ||
Duration of medication use | .130 | .343 | ||||||
Up to 10 days | 133 | (78.7) | (45.1) | (54.9) | (12.8) | (87.2) | ||
11 to 30 days | 29 | (17.2) | (31.0) | (69.0) | (3.4) | (96.6) | ||
More than 30 days | 7 | (4.1) | (14.3) | (85.7) | (14.3) | (85.7) | ||
Length of treatment | .355 | .108 | ||||||
Less than 1 month | 150 | (88.8) | (43.3) | (56.7) | (12.0) | (88.0) | ||
1 to 6 months | 16 | (9.4) | (25.0) | (75.0) | (0) | (100) | ||
More than 6 months | 3 | (1.8) | (33.3) | (66.7) | (33.3) | (66.7) | ||
Antiretroviral therapy | .007 | .323 | ||||||
3TC + TNF + LPV/RTV | 56 | (33.1) | (55.4) | (44.6) | (14.3) | (85.7) | ||
3TC + TNF + EFV | 78 | (46.2) | (34.6) | (65.4) | (10.3) | (89.7) | ||
3TC + TNF + ATV + RTV | 13 | (7.7) | (15.4) | (84.6) | (0) | (100) | ||
3TC + DDI + LPV/RTV | 15 | (8.9) | (60.0) | (40.0) | (6.7) | (93.3) | ||
Other | 7 | (4.1) | (14.3) | (85.7) | (28.6) | (71.4) | ||
Duration of antiretroviral use | < .001 | .650 | ||||||
Up to 6 months | 123 | (72.8) | (52.0) | (48.0) | (10.6) | (89.4) | ||
More than 6 months | 46 | (27.2) | (13.0) | (87.0) | (13.0) | (87.0) | ||
Previous VL relapse | < .001 | .056 | ||||||
Yes | 64 | (37.9) | (95.3) | (4.7) | (17.2) | (82.8) | ||
No | 105 | (62.1) | (8.6) | (91.4) | (7.6) | (92.4) | ||